Bumetanide

布美他尼

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameBumetanide
Drug Alias Name丁苯氧酸Bumetanida布米他奈Bumetanidas丁氧苯酸 +[14] 
ClassificationSmall molecules
Mechanisms of ActionSodium-(potassium)-chloride cotransporter 2 inhibitors
TargetsSodium-(potassium)-chloride cotransporter 2
Therapy Area/IndicationsAutism Spectrum DisorderPoisoningEdema +[13] 
Global Approved IndicationsPoisoningEdemaHyponatremia +[7] 
Approved Indications in ChinaPoisoningEdemaHyponatremia +[7] 
Original Approved Country/TerritoryJapan
Original Approved Date1976/04/08
Country/TerritoryCzechiaCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesKnight TherapeuticsItalian Institute of TechnologyYale University +[7] 
Inactive CompaniesShanghai Jiao Tong University School of MedicineValidus Pharmaceuticals LlcInstitut De Recherches Internationales Servier +[5] 
Active IndicationsPoisoningEdemaHyponatremia +[10] 
Inactive IndicationsAutism Spectrum DisorderParkinson DiseaseHypokalemic Periodic Paralysis

Other Information

ATC CodeC03CA02
Related LinksWikipediaDrugBankKEGG